Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT03634982
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
- NCT03634982 ↗
- Unknown
- Revolution Medicines, Inc.
- Focused
We haven't built an HCP commentary report on NCT03634982 (RMC-4630 in relapsed/refractory solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03634982 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants With Relapsed/Refractory Solid Tumors
- Phase
- Phase 1
- Status
- Unknown
- Conditions
- Solid Tumors
- Interventions
- RMC-4630
- Arms
- RMC-4630 · Experimental
- Enrollment
- 133
- Primary outcomes
- Number of participants with adverse events (AEs)
- Number of participants with dose limiting toxicities (DLTs)
- Sponsor
- Revolution Medicines, Inc. with Sanofi
- Start
- Sep 28, 2018
- Primary completion
- Mar 31, 2023 (estimated)
- Results posted
- No
- Registry record
- NCT03634982 · updated Sep 1, 2022